🟢 Abbott is trading 6.3% up in after-hours trading amid FDA approval of new CardioMEMS capabilities

Abbott is trading at $106.48, up 6.34% in after-hours trading, with FDA approval of new CardioMEMS capabilities a possible catalyst.

• On October 5, Abbott announced FDA approval of CardioMEMS HF System capabilities, including patient-facing features to support engagement in heart care.
• Regular-session close was $100.13 on October 5; after-hours price is up 6.34% per supplied context.
• No verified after-hours volume data was found; Abbott’s release does not explicitly link the approval to trading.